Related Experiment Video

Updated: May 26, 2026

The WATCHMAN Left Atrial Appendage Closure Device for Atrial Fibrillation
23:33

The WATCHMAN Left Atrial Appendage Closure Device for Atrial Fibrillation

Published on: February 28, 2012

Rivaroxaban (Xarelto) for acute coronary syndrome

    The Medical Letter on Drugs and Therapeutics
    |December 17, 2011
    PubMed

    Insights

    Adding low-dose rivaroxaban to antiplatelet therapy after acute coronary syndrome (ACS) reduces cardiovascular events. This strategy did not increase fatal bleeding, offering a new treatment option for ACS patients.

    Area of Science:

    • Cardiology
    • Pharmacology

    Background:

    • Standard acute coronary syndrome (ACS) treatment involves dual antiplatelet therapy plus anticoagulation during hospitalization, followed by antiplatelet monotherapy.
    • Adding warfarin to dual antiplatelet therapy is generally avoided due to bleeding risks and variable anticoagulant effects.

    Purpose of the Study:

    • To evaluate the efficacy and safety of adding low-dose rivaroxaban to antiplatelet therapy in ACS patients post-discharge.

    Main Methods:

    • A clinical trial investigated the addition of low-dose rivaroxaban to standard antiplatelet therapy in patients after ACS.

    Main Results:

    • The addition of rivaroxaban significantly reduced major cardiovascular events.
    • No increase in fatal bleeding was observed with the addition of rivaroxaban.

    Conclusions:

    • Low-dose rivaroxaban combined with antiplatelet therapy is a promising strategy for reducing cardiovascular events in ACS patients.
    • This regimen offers a potential improvement over standard therapy by enhancing efficacy without a prohibitive increase in fatal bleeding risk.

    More Related Videos

    Rapid Point-of-Care Assay of Enoxaparin Anticoagulant Efficacy in Whole Blood11:17

    Rapid Point-of-Care Assay of Enoxaparin Anticoagulant Efficacy in Whole Blood

    Published on: October 12, 2012

    Related Concept Videos

    Acute Coronary Syndrome I: Introduction01:30

    Acute Coronary Syndrome I: Introduction

    Acute Coronary Syndrome (ACS) encompasses a spectrum of heart conditions caused by sudden obstruction of coronary arteries, typically resulting from the rupture of an atherosclerotic plaque and subsequent thrombus (blood clot) formation. This obstruction can lead to partial or complete blockage of blood flow, causing varying degrees of myocardial ischemia or infarction.ACS includes the following clinical entities:Unstable Angina (UA)Non-ST-Elevation Myocardial Infarction (NSTEMI)ST-Elevation...
    Acute Coronary Syndrome III: Diagnostic Studies01:30

    Acute Coronary Syndrome III: Diagnostic Studies

    Diagnosing acute coronary syndrome or ACS begins with a thorough patient history. Notable symptoms include central, crushing chest pain radiating to the left arm, neck, jaw, or back, along with shortness of breath, sweating (diaphoresis), nausea, vomiting, dizziness, and palpitations.It is crucial to note any history of cardiac illnesses and assess risk factors, including age, gender, smoking, hypertension, diabetes, hyperlipidemia, and a sedentary lifestyle.During physical examination, vital...
    Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants01:18

    Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants

    Oral anticoagulants are vital tools in preventing and treating blood clotting disorders. This diverse class of medications can be categorized as vitamin K antagonists, exemplified by warfarin, and direct thrombin inhibitors (DTIs), such as dabigatran, as well as factor Xa inhibitors, including rivaroxaban.
    Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
    Acute Coronary Syndrome IV: Interprofessional Care01:28

    Acute Coronary Syndrome IV: Interprofessional Care

    IntroductionThe management of Acute Coronary Syndrome (ACS) aims to minimize myocardial damage, preserve myocardial function, and prevent complications.Initial ManagementInpatient management involves continuous cardiac monitoring, preferably in an ICU, focusing on blood pressure, serum sodium, potassium, and creatinine levels, and urine output. Ongoing pharmacologic management is crucial for stabilizing the patient.Supplemental Oxygen: Administer supplemental oxygen if oxygen saturation is...
    Acute Coronary Syndrome V: Nursing Management01:26

    Acute Coronary Syndrome V: Nursing Management

    Nursing Assessment:Nursing management of acute coronary syndrome (ACS) involves taking the patient's history, focusing on primary complaints such as chest pain, dyspnea, and excessive sweating (diaphoresis), as well as other symptoms like back or jaw pain, nausea, vomiting, palpitations, dizziness, and fatigue. The nurse also reviews the patient's history of cardiac events, risk factors such as hypertension, diabetes, smoking, family history, and current medications.In the objective assessment,...
    Acute Coronary Syndrome II: Pathophysiology and Clinical Manifestations01:19

    Acute Coronary Syndrome II: Pathophysiology and Clinical Manifestations

    The pathophysiology of Acute Coronary Syndrome [ACD] involves several key processes:The main underlying cause of ACD is atherosclerosis, a chronic inflammatory disease characterized by the buildup of lipid-laden plaques within the coronary arteries.As the atherosclerotic plaque grows in the coronary artery, it may become unstable due to the formation of a lipid-rich core and a thin fibrous cap. Inflammatory cells within the plaque, such as macrophages, secrete enzymes that degrade the...